The 2004 PT Section Education Committee took the first steps in addressing the charge: "How can the supply of highly qualified pharmaceutical scientist specialists in product development and related technologies that meet current and future needs be ensured?" This charge was borne out of earlier reports and current experience that suggest that: (1) graduate programs in colleges of pharmacy are increasingly failing to produce sufficient numbers of appropriately qualified specialists in product development and related pharmaceutical technologies and, (2) the pharmaceutical industry has been forced to recruit and train scientists from other disciplines. Surveys conducted by this committee of the membership (PT, PDD and BT sections) and a representative group of pharmaceutical executives validated this concern and provided insight into its nature and depth. For example, the executives reported that 50% or less of product development staff have undergraduate degrees in pharmacy and that 50% or less have advanced degrees in pharmaceutics/industrial pharmacy/pharmaceutical technology, yet entry-level PhDs in these specialties bring a better mix of skills to the product development table than their counterparts from other science disciplines, and that this advantage persist even after 4-6 years experience on the job. And the great difficulty in finding candidates with the right mix of experience and education was also made clear by the surveys. Based in part on an analysis of these surveys, this committee developed an extensive list of issues to be addressed by future PT Education committees and AAPS. Among these were: (1) Should AAPS encourage and assist in the establishment of graduate programs in product development/technology and/or tracks in academic institutions whether or not they are colleges of pharmacy?, (2) Should AAPS develop standards for and qualify such educational programs and tracks? (3) How do we and what role should AAPS play in creating awareness in colleges and universities of our needs and the incentives to develop and maintain programs that meet these needs?, and (4) How can stable funding be provided for programs in product development and technology?
INTRODUCTION AND BACKGROUND
Concern over the adequacy of the supply of pharmaceutical scientists is not new, having been expressed as early as 1978 in a Symposium of Teachers of Pharmacy (Pharmaceutics) held at the 25 th National Meeting of the A.Ph.A. Academy of Pharmaceutical Sciences. 1 Among others, the presenters and numerous participant comments emphasized (a) the lack of financial support and its impact, (2) the potential negative impact of the growing clinical emphasis in undergraduate programs in pharmacy, (3) the types and sources of funding available, and (4) the role that could be played by cooperative programs between academia and the industry. Based on a survey of~25 each of industrial managers and academicians, R.V. Smith 2 observed in 1981 that a great need exists for PhD pharmaceutics scientists in industry, and that most acutely, that shortage is in the area of industrial/ physical pharmacy. Based on this analysis, he noted that the following factors can be considered as contributing to this situation: (a) a shift in the interest of graduate students toward more "biological-type" sciences, (b) the movement of faculty during the previous 10 years more toward biopharmaceutics and pharmacokinetics, (c) the substantial investment in the equipment, space and faculty needed for industrial pharmacy programs has apparently been viewed as prohibitive by academic administrators, and (d) the lack of support from both federal sources and the industry itself.
A 1990 AAPS Task Force on academic pharmaceutics 3 (composed primarily of academics) observed that even though pharmaceutics has provided much of the intellectual stimulus for the development of clinical pharmacy, this did not result in pharmacy students having an enhanced interest in academic pharmaceutics per se because most students enter pharmacy school to become pharmacy practitioners. It was further noted 3 that "if the very substantial demand for pharmaceutical scientists" cannot be met by pharmacy schools, then industry and academia will turn increasingly toward other discipline areas to meet manpower needs and attempt to compensate for lack of pharmaceutical education and training in such individuals by providing in-house and commercially available training programs. It was argued that "This practice is unsound and could create a vicious cycle whereby the limited availability of newly graduated pharmaceutical scientists eventually reduces the demand for them…" 3 In 1997, Alice Till observed that today's graduate programs are "training the majority of students for the minority of industrial opportunities." 4 Dr. Till explained that graduate programs are more and more focusing on drug discovery, and that basic research is often emphasized over applied research. This situation may be the result of specific faculty interests, funding issues or a lack of understanding of the wants and needs of industry, but the net result is that programs in industrial pharmacy or pharmaceutical manufacturing have been de-valued, and programs in material science, formulation science or process science are uncommon. 4 More recently, Mooney, 5 in addressing the manpower needs of the pharmaceutical industry at a EUFEPS workshop, pointed out that the output from universities is not keeping up with the demands of the pharmaceutical and healthcare industries for science and engineering graduates who can "rapidly contribute to success in the business environment," and that the challenge "comes from balancing education in basic science with training in the emerging areas of science and technology." Addressing a European audience, Mooney noted that academia and industry will need to work together more synergistically, government funding should be prioritized to taken into account industry's needs, and that multi-disciplinary programs are going to be more and more important. At that same workshop, Breimer 6 also called for updated, multi-disciplinary programs, pointing to the fact that new developments in drugs (eg, new classes of mechanismbased small molecules, proteins, oligonucleotides, and others) each bring a need for new challenges to quality, production, delivery systems and formulation, among others. Both Breimer and Mooney also emphasized the need for several "softer" and/or non-disciplinary skills such as written and verbal communication skills, ability to function in interdisciplinary teams, and exposure to social and cultural skills needed for an increasingly globalized industry.
Interestingly, the authors of the report the 1998 Commission on the Future of Graduate Education in the Pharmaceutical Sciences 7 later observed in 2002 that the "recent dramatic increases in the federal support of biomedical research, specifically the doubling of the NIH budget, is producing an excess of PhD graduates in the biomedical sciences." 8 They suggested that this increase in graduate program enrolment is driven more by personnel needs of the academic research community and less by employment needs or even the educational needs of graduate students. It is perhaps ironic that one outcome of this situation is that the post-doctoral fellowship has become a virtually required component of higher education in such disciplines.
HYPOTHESES
Based on the personal experience of the committee and a review of the literature, the following hypotheses related to the supply of pharmaceutical scientists specializing in product development and related technologies were adopted:
Shift in Focus of Pharmacy Education
The focus of pharmacy education has been shifting away from the basic sciences. In most cases schools have been setting new priorities to conform to changes in pharmacy practice and new initiatives in health care. In many cases, graduate programs in colleges of pharmacy are focusing increasingly on drug discovery and biotechnology and other basic areas while applied programs in industrial pharmaceutics, product development and pharmaceutical technology are often devalued.
Limited Number of programs in Industrial Pharmaceutics and Related Technologies
There presently are a limited number of programs in industrial pharmaceutics, product development and pharmaceutical technology in academia, and this number is likely to diminish. When currently established faculty in these areas retire, typically they are not replaced with specialists in those same areas. The high capital cost of technology research discourages the entry of faculty and the establishment of new programs. This situation could create a critical shortage of trained personnel for industry.
Industry Continues to Need and Value Our Graduates
Graduates are so strongly recruited that post-doctoral assignments are almost unheard of. Graduates in industrial pharmaceutics/technology are often committed to positions in the industry before all degree requirements have been completed. To meet its needs, it appears that the pharmaceutical industry has been turning more and more to scientists from other scientific areas only to train them in pharmaceutical research and development.
There is a Lack of Stable Funding for Technologically-Focused Programs
Funding is generally derived from the industry and is often short-term or project-based, thereby not providing the stability of the multiple-year grants and contracts common in federal funding. Industry funding often does not support Federal levels of overhead. Furthermore, faculty who secure such funding and their schools may not be given "full recognition" for bringing in the money because it is not "peer reviewed." This situation provides another serious disincentive for pharmacy schools and faculty to develop and nurture programs in industrial pharmaceutics/technology.
FIRST STEP
The Committee agreed that that the first step in addressing its charge should be to document the problem. It is important to find out, for example, who are the people doing technology and formulation and what their educational background is. It is also important to examine the industry's attitude, position and needs are re this issue. To that end, two surveys were created: 1) A web-based survey of the membership.
2) A focused survey directed to executives in representative sectors of the industry.
Following is a discussion of the design and implementation of these surveys and an analysis of the responses.
MEMBERSHIP SURVEY
The member survey was web-based and targeted the PT, PDD and BT sections. Of the roughly 5000 sent, there were a total of 398 responses.
Demographics
About half of responders indicated PT as their primary section membership, followed by 38.5% for PDD and 10.6% for BT. For nearly 70%, the PhD is their highest degree. Nearly 60% of responders obtained their highest degree in an area of pharmaceutics (ie, physical pharmacy, industrial pharmacy, dosage forms and drug delivery). The second most common discipline for their highest degree was chemistry (16.1%). Nearly half (47.2%) of responders hold a position that could be described as scientist/senior scientist/research fellow or equivalent. Significantly, nearly a third of respondents (29.8%) were managers, directors, section heads or their equivalent, while another 12.9% identified themselves 
EXECUTIVE SURVEY
Although the Member Survey was clearly informative, the PT Education Committee considered that a focused survey directed to pharmaceutical executives would provide an additional perspective to the problem. A list of more than 50 executives was compiled from the suggestions of the committee. They were presidents (10%), vice presidents (40%), various levels of directors (42%) and others (8%). The Executive Survey was a hardcopy questionnaire sent with a postage paid return envelop. Fourteen responses have been received to date for a 27% return rate. 
Demographics
More than 90% consider PT their primary section. All respondents have been in the pharmaceutical industry for 11 or more years, of which 57% have been in this industry for more than 20 years. The highest degree of respondents was either a PhD (86%) or a Masters degree (14%) and is most likely (86%) to be in pharmaceutics (defined as physical pharmacy, industrial pharmacy, product development).
Questions and Responses
1. What percentage of staff engaged in product development activities in your firm or division has an undergraduate degree in pharmacy regardless of what discipline their advanced degree(s) are:
• 7(50%) 0%-10%
• 4(29%) 11%-25% • 1(7%) 26%-50%
• 2(14%) 51%-75%
• 0% 975% 2. What percentage of staff engaged in product development activities in your firm or division has an advanced degree in pharmaceutics/industrial pharmacy/pharmaceutical technology?
3. What percentage of staff engaged in product development activities in your firm or division only has an entry level or advanced degree in an engineering field?
• 9(64%) 0%-10%
• 4(29%) 11%-25%
• 0(0%) 26%-50%
• 1(7%) 51%-75%
• 0% 975% 4. What percentage of staff engaged in product development activities in your firm or division only has an entry or advanced degree in other science fields (physical chemistry, physics, organic chemistry, biochemistry, etc.)
5. On scale of 0 to 4 (0 = more qualified candidates than openings; 4 = cannot fill current positions), how would you rate the level of difficulty in finding qualified people to fill product development positions?
• 0(0%) 1
Respondants were also asked to elaborate on their answer by making written comments. Following is a representative list of their comments: (1) Direct formulation expertise coupled with communication skills are hard to find;(2) Difficult to find "formulation" candidates; (3) Pharmacy and pharmaceutics almost impossible -especially those with some • 4(29%) 0%-10%
• 2(14%) 11%-25%
• 6(43%) 26%-50%
• 2(14%) 51%-75% 975% • 1(7%) 0%-10%
• 7(50%) 11%-25%
• 3(21%) 26%-50%
• 3(21%) 51%-75% 975% 
SUMMARY ANALYSIS

Desired Background and Experience for Entry-Level Pharmaceutical Scientists in Product Development Groups
Taken as a whole, both surveys support the idea that entrylevel product development scientists should bring to the position a good basic sciences background, but, in particular, be strong in preformulation, materials science and unit operations. Bringing the appropriate background to the job is preferable to having a good basic science background and picking up these additional skills on the job. A working knowledge of patents, SOPs, INDs, NDAs and ANDAs should also be a part of the entry level pharmaceutical scientist. About half of members surveyed opined that currently available education/training of entry-level PhD pharmaceutical scientists is adequate preparation for product development.
Who Is Doing Product Development?
Executives report that 50% or less of product development staff have undergraduate degrees in pharmacy and that 50% or less have advanced degrees in pharmaceutics/industrial pharmacy/pharmaceutical technology. According to more than 90% of executives, no more than 25% of their product development staff have either undergraduate or graduate degrees in an engineering field, but up to 75% of staff have entry level or advanced degrees in other science fields (eg, physical chemistry, physics, organic chemistry, biochemistry, etc).
Availability of Entry-Level Scientists with Appropriate Backgrounds in Product Development and Pharmaceutical Technology
Most members surveyed supported that there is not only a shortage of entry-level scientists with appropriate background in product development and pharmaceutical technology, but also a lack of suitably experienced pharmaceutical scientists seeking employment. This situation was most obvious in the survey of executives, 70% of whom reported that the level of difficulty in filling such positions 3 or higher on a 4-point scale (4 = greatest difficulty). Most executives observed that there was substantial difficulty in finding the right mix of experience and education. According to the executives, when recruiting for product development positions, less than half the positions require a technical background in biology and drug delivery; whereas,~90% require a technical background in physical science and pharmaceutical technology. The executives report and most members agree that firms go to extraordinary efforts to recruit for product development, using every means available, including going "deep" into the network. 
Comparison of a PhD in Industrial Pharmacy, Pharmaceutical Technology or Related Area to Graduates of Other Science Disciplines
The majority of the members surveyed who expressed an opinion indicated that they would not prefer to hire PhD level chemists and chemical engineers and have them learn on the job to fill current voids and needs for scientists in product development and pharmaceutical technology.
Entry-level PhDs in industrial pharmacy, pharmaceutical technology or related areas bring a better mix of skills to the product development table than their counterparts from other science disciplines, and this advantage persist even after 4-6 years experience on the job. Assuming 0-2 years experience, 80% or more of the executives felt that a PhD in industrial pharmacy, pharmaceutical technology or related area to graduates was much better or somewhat better than graduates of other science disciplines in knowledge of dosage forms and drug delivery, formulation skills, and knowledge of manufacturing unit processes. About 50% opined that their problem solving skills were somewhat better or much better than that of graduates of other sciences, and 43% felt that they were about equivalent in problem solving skills. About 64% felt that their basic science Figure 6 . How pharmaceutical executive respondants compared a PhD in industrial pharmacy, pharmaceutical technology or related areas with 0-2 years experience to graduates of other science disciplines they have seen with the same level of experience. E9 skills were equal to or better than those of graduates of other science disciplines.
Assuming 4-6 years experience, 90% or more of the executives felt that a PhD in industrial pharmacy, pharmaceutical technology or related area to graduates was much better or somewhat better than graduates of other science disciplines in knowledge of dosage forms and drug delivery and formulation skills, and 79% felt that their knowledge of manufacturing unit processes was somewhat better or much better than graduates of other science disciplines. About 50% opined that their problem solving skills were somewhat better or much better than that of graduates of other sciences, and 43% felt that they were about equivalent in problem solving skills. 100% felt that their problem solving skills were equal to or better than those of graduates of other science disciplines; whereas, 79% felt that their basic science skills were about equal to or better than those of graduates of other science disciplines.
What Sources and/or Solutions to the Problem Are Revealed in the Surveys?
These questions were only superficially addressed, and only in the member survey. Members broadly recognized that fewer United States colleges of pharmacy focus on product development. Those expressing an opinion (975%), agreed (2 to 1) that the pharmaceutical industry should assume greater responsibility in funding university professors to continue the supply of future scientists to the industry. Concern was expressed by a 2 to 1 majority of the 975% of members who expressed an opinion that a decline in United States trained scientists will result in the exportation of product development to foreign countries.
What Do AACP Faculty/PhD Productivity Data Teach Us?
It is interesting to reflect on the above conclusions in light of recent statistical data from AACP. 9 Below are two graphs 
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plotting by discipline the trends since 1980 in PhD degrees granted and faculty numbers in colleges of pharmacy. It is clear from these data that the numbers of 'basic sciences' faculty in colleges of pharmacy, particularly those identified as 'pharmaceutics' faculty have been relatively flat; whereas, there has been a dramatic increase in practice faculty. This observation clearly reflects a shift in emphasis in pharmacy schools (Figure 8 ).
Yet, this relatively static number basic sciences faculty has apparently produced a growing number of PhDs, especially in pharmaceutics, since 1980 ( Figure 9 ).
However, these statistics do not necessarily support that academic pharmacy is rising to the challenge of supplying entry-level scientists with appropriate background in product development and pharmaceutical technology. Clearly, industry's need is acute and persistent. The definition of 'pharmaceutics' research is quite broad and varies substantially from institution to institution. These data more likely indicate that pharmaceutics faculty have shifted to areas more easily funded through peer review sources (eg, pharmacokinetics, transporters, cellular metabolism, and other biosciences) than that they are producing specialists in product development and related technologies. AACP does not break out the subdisciplines nor the sources of support in these surveys. 
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NEXT STEPS
Future PT Education committees should focus on the following non-limiting list of topics:
1. Exactly what are the current and future personnel needs and the skill sets they should have? a) What are the current and anticipated future skill-set needs for pharmaceutical scientists specializing in product development and related technologies?
b) The ability to integrate basic sciences with practical application, and the ability to work effectively in an increasingly interdisciplinary environment are frequently cited as important attributes. How do we foster those abilities? "The scientific and technical challenges on the critical path towards the "desired state" are significant. The traditional empirical approaches will need to be replaced with a much more fundamental scientific understanding. This will require the talent and know-how of many scientific and technical disciplines. Without sufficient and sustained support our Nation's pharmaceutical education and research system will be unable to meet the needs of the desired state. Significant collaboration and cooperation among industry, academia, and public agencies (eg, National Science Foundation and National Institutes of Health) including FDA will be necessary to find solutions to this challenge." 10 A corollary to this is whether traditional programs in pharmaceutics or industrial pharmacy training alone are sufficient to meet these challenges and be competitive for public funds. See 2d above.
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